Holen Sie sich die Stockscreener-App
0.00
100.00%
-3.65
Schlusskurs vom Vortag:
$3.65
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$378.94M
Einnahmen:
$234.04M
Nettoeinkommen (Verlust:
$-323.92M
KGV:
0.00
EPS:
-3.8
Netto-Cashflow:
$-223.46M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$6.65
Revance Therapeutics Inc Stock (RVNC) Company Profile
Firmenname
Revance Therapeutics Inc
Sektor
Branche
Telefon
(615) 724-7755
Adresse
1222 DEMONBREUN STREET, NASHVILLE, CA
Vergleichen Sie RVNC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVNC
Revance Therapeutics Inc
|
0.00 | 378.94M | 234.04M | -323.92M | -223.46M | -3.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Revance Therapeutics Inc Stock (RVNC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-29 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-01-09 | Herabstufung | Goldman | Buy → Neutral |
| 2023-08-16 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-22 | Eingeleitet | Goldman | Buy |
| 2021-10-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-15 | Bestätigt | Needham | Buy |
| 2020-08-11 | Fortgesetzt | Mizuho | Buy |
| 2020-03-23 | Herabstufung | Goldman | Buy → Neutral |
| 2019-12-02 | Eingeleitet | Goldman | Buy |
| 2019-10-30 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-02-15 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-01-29 | Eingeleitet | Stifel | Buy |
| 2018-11-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2018-09-17 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-04-20 | Bestätigt | Mizuho | Buy |
| 2018-03-27 | Eingeleitet | Needham | Buy |
| 2018-03-05 | Eingeleitet | Goldman | Buy |
| 2018-01-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2017-12-06 | Eingeleitet | Guggenheim | Buy |
| 2017-12-06 | Bestätigt | Mizuho | Buy |
| 2017-11-27 | Eingeleitet | Barclays | Overweight |
| 2017-11-17 | Eingeleitet | Mizuho | Buy |
| 2017-08-22 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Revance Therapeutics Inc Aktie (RVNC) Neueste Nachrichten
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Two Sigma Investments LP Acquires 13,539 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Ameriprise Financial Inc. Raises Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Investor Network: Revance Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
BNP Paribas Financial Markets Sells 10,728 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Deutsche Bank AG Grows Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Jane Street Group LLC Sells 491,504 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
ProShare Advisors LLC Increases Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Rating of “Hold” by Brokerages - Defense World
Millennium Management LLC Increases Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Announces Blue Lizard® Australian Sunscreen Times Square Takeover to Celebrate National Sunscreen Day - The Malaysian Reserve
The Gross Law Firm Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – RVNC - Louisiana First News
Northern Trust Corp Has $3.01 Million Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at Wall Street Zen - Defense World
Revance Names New CEO to Drive Next Phase in Aesthetic Innovation - Global Cosmetics News
Revance Announces Blue Lizard Australian Sunscreen® Partnership with The Bentway for Their Summer 2025 Sun/Shade Program - The Malaysian Reserve
Revance Announces Leadership Succession Plan to Support Next Phase of Growth and Innovation - Longview News-Journal
Price T Rowe Associates Inc. MD Purchases 7,839 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - ACCESS Newswire
Dermata Therapeutics, Inc. SEC 10-Q Report - TradingView
Revolutionary Once-Weekly Natural Acne Treatment Achieves Breakthrough in Phase 3 Trial Results - Stock Titan
Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com - Defense World
Hsbc Holdings PLC Cuts Stock Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Lost Money on Revance Therapeutics, Inc. (RVNC)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Shareholders that Lost Money on Revance Therapeutics, Inc. (RVNC) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Revance Therapeutics, Inc. Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information - ACCESS Newswire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Acquired by Wells Fargo & Company MN - Defense World
Revance Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationRVNC - ACCESS Newswire
MetLife Investment Management LLC Has $184,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Analysts Set Revance Therapeutics, Inc. (NASDAQ:RVNC) PT at $8.39 - Defense World
Invesco Ltd. Boosts Holdings in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Revance Therapeutics (NASDAQ:RVNC) Earns Hold Rating from Analysts at StockNews.com - Defense World
Spasticity Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Jazz Pharmaceuticals, Revance Therapeutics, Ipsen - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by LPL Financial LLC - Defense World
Revance Announces Blue Lizard® Australian Sunscreen Named the #1 Selling Mineral Sunscreen Brand - StreetInsider
Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com - Defense World
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineRVNC - ACCESS Newswire
Geode Capital Management LLC Raises Position in Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Investigation announced for Long-Term Investors in Revance - openPR.com
Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance - insights.citeline.com
JPMorgan Chase & Co. Sells 2,335,359 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) - Defense World
Finanzdaten der Revance Therapeutics Inc-Aktie (RVNC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.91%
1.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):